Brokerages Set Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Price Target at $18.75

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $18.75.

Several research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. B. Riley Financial reiterated a “buy” rating and issued a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Guggenheim reiterated a “buy” rating and set a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Wall Street Zen raised Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Benchmark restated a “speculative buy” rating and issued a $15.00 price objective (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday, August 20th.

Institutional Investors Weigh In On Unicycive Therapeutics

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Unicycive Therapeutics during the second quarter worth approximately $55,000. Vanguard Group Inc. raised its position in Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after buying an additional 52,925 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Unicycive Therapeutics during the third quarter worth about $512,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at approximately $182,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Price Performance

NASDAQ UNCY opened at $5.29 on Monday. The stock’s 50 day simple moving average is $5.27 and its 200-day simple moving average is $6.48. The company has a market cap of $147.33 million, a PE ratio of -3.02 and a beta of 1.79. Unicycive Therapeutics has a 1-year low of $3.71 and a 1-year high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.41. On average, equities research analysts anticipate that Unicycive Therapeutics will post -1.17 EPS for the current fiscal year.

More Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Negative Sentiment: Several firms, including Kaplan Fox, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and Faruqi & Faruqi, reminded investors that a class action has been filed against Unicycive and certain officers. The case covers investors who purchased securities from December 29, 2025, through June 29, 2026, with November 2, 2026, set as the deadline to seek lead-plaintiff status. Kaplan Fox class action notice
• Negative Sentiment: The lawsuit-related notices allege that Unicycive misled investors about the timing of an FDA decision for oxylanthanum carbonate and the potential commercial launch of the kidney-disease treatment. The allegations also claim the company had not inspected a third-party manufacturing facility that had previously contributed to a Complete Response Letter. These claims have not been proven in court. Unicycive shareholder alert
• Negative Sentiment: The volume of law-firm announcements over the past two days increases the visibility of potential litigation costs, regulatory and execution risks, and uncertainty surrounding Unicycive’s lead drug candidate. One notice cited a 39.1% share-price decline on June 30 following unusually heavy trading, intensifying investor concern. Levi and Korsinsky lawsuit reminder

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.